SGLT2 inhibitor empagliflozin alleviates cardiac remodeling and contractile anomalies in a FUNDC1-dependent manner in experimental Parkinson’s disease
Wei Yu, Lin Wang, Weiying Ren, Haixia Xu, Ne N. Wu, Donghui Yu, Rüssel J. Reiter, Wenliang Zha, Qingdong Guo, Jun Ren
Topics & Concepts
MitophagyVDAC1MPTPParkinFIS1PINK1EndocrinologyEmpagliflozinInternal medicineMFN2MitochondrionBiologyCell biologyChemistryMedicineAutophagymitochondrial fusionApoptosisParkinson's diseaseDiseaseBiochemistryGeneBacterial outer membraneEscherichia coliType 2 Diabetes MellitusMitochondrial DNADiabetes mellitusAutophagy in Disease and TherapyParkinson's Disease Mechanisms and TreatmentsElectrospun Nanofibers in Biomedical Applications